| Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study H Abu-Sbeih, FS Ali, D Alsaadi, J Jennings, W Luo, Z Gong, DM Richards, ... Journal for immunotherapy of cancer 6, 1-11, 2018 | 178 | 2018 |
| Immune checkpoint inhibitor–mediated diarrhea and colitis: a clinical review Z Gong, Y Wang JCO Oncology Practice 16 (8), 453-461, 2020 | 58 | 2020 |
| Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia Z Gong, LJ Medeiros, JE Cortes, L Zheng, JD Khoury, W Wang, G Tang, ... Blood cancer journal 7 (7), e583-e583, 2017 | 50 | 2017 |
| Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy Z Gong, LJ Medeiros, JE Cortes, Z Chen, L Zheng, Y Li, S Bai, P Lin, ... Blood advances 1 (26), 2541-2552, 2017 | 46 | 2017 |
| Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: assessment of potential value JE Hidalgo‐Lόpez, R Kanagal‐Shamanna, AE Quesada, Z Gong, ... Cancer 124 (19), 3849-3855, 2018 | 33 | 2018 |
| Stent implantation in patients with metal allergy: a systemic review and meta-analysis Z Gong, M Li, X Guo, Z Ma, J Shi Coronary Artery Disease 24 (8), 684-689, 2013 | 29 | 2013 |
| Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome H Kurt, L Zheng, HM Kantarjian, G Tang, F Ravandi-Kashani, ... Modern Pathology 31 (7), 1141-1154, 2018 | 25 | 2018 |
| Comparison of treatment modalities in pancreatic pseudocyst: A population based study Y Wang, YA Omar, R Agrawal, Z Gong World journal of gastrointestinal surgery 11 (9), 365, 2019 | 21 | 2019 |
| Extranodal nasal-type natural killer/T-cell lymphoma with penile involvement: a case report and review of the literature X Wang, Z Gong, SX Li, W Yan, Y Song BMC urology 17, 1-6, 2017 | 14 | 2017 |
| Microarray expression profiles of long non-coding RNAs in germinal center-like diffuse large B-cell lymphoma HY Gao, B Wu, W Yan, ZM Gong, Q Sun, HH Wang, W Yang Oncology reports 38 (3), 1363-1372, 2017 | 14 | 2017 |
| Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy Z Gong, L Zheng, Z Tang, Z Chen, W Wang, S Bai, G Tang, ... Annals of hematology 96, 501-504, 2017 | 11 | 2017 |
| Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia Z Chen, LJ Medeiros, HM Kantajian, L Zheng, Z Gong, KP Patel, H Xiong, ... Blood cancer journal 7 (2), e521-e521, 2017 | 11 | 2017 |
| The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma S Hao, X Lu, Z Gong, RL Bassett, S Hu, SN Konoplev, G Tang, S Li, J Xu, ... Modern Pathology 34 (2), 327-335, 2021 | 10 | 2021 |
| Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non … MR Hussain, FS Ali, D Verghese, PT Myint, M Ahmed, Z Gong, Y Gerais, ... Critical Reviews in Oncology/Hematology 169, 103526, 2022 | 9 | 2022 |
| Outcomes of Immune Checkpoint Inhibitor–related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections W Ma, Z Gong, H Abu-Sbeih, Y Peng, F Peng, F Zou, A Charabaty, ... American Journal of Clinical Oncology 44 (8), 402-408, 2021 | 7 | 2021 |
| Concomitant deletion of the short arm (del (1p13. 3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical … M Mohan, Z Gong, TC Ashby, S Al Hadidi, S Thanendrarajan, C Schinke, ... Cancer 129 (16), 2491-2498, 2023 | 5 | 2023 |
| Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of … F Ali, MR Hussain, A Deep, H Abu-Sbeih, T Alrifai, PT Myint, Z Gong, ... Journal of Clinical Oncology 37 (15_suppl), e14117-e14117, 2019 | 4 | 2019 |
| Mixed phenotype blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy Z Gong, S Bai, S Hu Blood, The Journal of the American Society of Hematology 128 (22), 5438-5438, 2016 | 4 | 2016 |
| Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study Z Gong, G Umoru, J Monge, N Shah, GR Mohyuddin, SV Radhakrishnan, ... Blood cancer journal 14 (1), 36, 2024 | 3 | 2024 |
| Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer EA Burns, K Gee, RB Kieser, J Xu, Y Zhang, A Crenshaw, IN Muhsen, ... Cancers 15 (1), 81, 2022 | 3 | 2022 |
